Abstract
The International Society for the Clinical Electrophysiology of Vision (ISCEV) standard for full-field electroretinography (ERG) describes a minimum set of tests, but encourages the use of additional protocols for clinical ERG testing. This extended protocol describes recording methods and derivations that will allow analysis of rod-driven components of the dark-adapted (DA) strong flash ERG a-wave, more closely related to rod phototransduction than ISCEV standard DA ERGs. The method involves recording ERGs to a flash strength equivalent to 30 cd s m2 under conditions of dark adaptation and additionally to the same stimulus following light adaptation (LA) and in the presence of a standard photopic background luminance of 30 cd m−2. The isolated rod-driven ERG a-wave is derived by subtracting the LA response from the DA ERG. The method is likely to be of value in the characterization of retinal disorders which affect rod quantal catch, diseases that affect the dynamics of any component of the activation phase of rod phototransduction, or those affecting total numbers of rod photoreceptors.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Jeffrey, Brett G 2 ; Mahroo, Omar A 3 ; Radouil, Tzekov 4 1 Aerpio Therapeutics, Cincinnati, USA (GRID:grid.417420.4)
2 National Eye Institute, Ophthalmic Genetics and Visual Function Branch, Bethesda, USA (GRID:grid.280030.9) (ISNI:0000 0001 2150 6316)
3 Moorfields Eye Hospital, London, UK (GRID:grid.439257.e) (ISNI:0000 0000 8726 5837); University College London, Institute of Ophthalmology, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
4 University of South Florida, Department of Ophthalmology, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X); University of South Florida, Department of Medical Engineering, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)





